Bortezomib in refractory ANCA-associated vasculitis: a new option?

P. Novikov,S. Moiseev,N. Bulanov,E. Shchegoleva
DOI: https://doi.org/10.1136/annrheumdis-2015-207947
IF: 27.973
2015-07-21
Annals of the Rheumatic Diseases
Abstract:Bortezomib is a proteasome inhibitor approved for the treatment of multiple myeloma. Proteasome inhibition depletes short-lived and long-lived plasma cells and is a promising therapeutic approach to treat refractory antibody-mediated autoimmune diseases. In a small uncontrolled study from Charite (Berlin), recently published in the Annals of the Rheumatic Diseases , 12 patients with systemic lupus erythematosis (SLE) with persistent disease activity and autoantibody production despite immunosuppression were treated with bortezomib according to the approved protocol for multiple myeloma.1 Disease activity declined significantly, though adverse events occurred in 11 of 12 patients and resulted in discontinuation of bortezomib in seven of them. Resistance to immunosuppressive treatment, including cyclophosphamide (CYC) and …
What problem does this paper attempt to address?